Fosun International — Fosun Wanbang Pharma Group
Tracked across 2 events · 16 articles · First seen Jul 01, 2026 · Last active Aug 27, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Fosun International — Fosun Wanbang Pharma Group, a wholly-owned subsidiary of Fosun Pharmaceutical Group, has secured the rights to develop, register, manufacture, and commercialize roconkibart in the Greater China region, enriching its immunology and inflammation portfolio.
Jul 01, 2026 · 8 articles
Business
Impact: Licensed rights to develop and commercialize roconkibart in Greater China; pays upfront and milestones to Junshi.
Aug 26, 2026 · 8 articles
ERGEN INTELLIGENCE
Track Fosun International — Fosun Wanbang Pharma Group live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard